NICE Technology Appraisals About Medicines: Formulary Adherence Checklist This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS. Last updated 08-Mar-16 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 01/06/2015 Omalizumab (Xolair) is recommended as a possible treatment for people aged 12 years and over with severe chronic spontaneous urticaria if: •a doctor has objectively diagnosed the condition as severe •the condition has not improved with standard treatment with TA339 - Omalizumab H1‑antihistamines or leukotriene receptor antagonists for previously treated •the drug is stopped at or before the fourth dose if the condition has not X 30/08/2015 21/09/2015 112 chronic spontaneous responded urticaria •the drug is stopped at the end of a course of treatment (6 doses) if the condition has responded, and is only restarted if the condition comes back •the drug is given by a secondary care specialist in dermatology, immunology or allergy. 1 01/06/2015 Ustekinumab (Stelara) is recommended as a possible treatment, alone or with a drug called methotrexate, for adults with active psoriatic arthritis when treatment with non-biological disease-modifying antirheumatic drugs (or TA 340 - Ustekinumab DMARDS) has not worked well enough if: for treating active psoriatic arthritis (rapid X 30/08/2015 20/07/2015 49 •treatment with tumour necrosis factor (TNF) alpha inhibitors is not suitable for review of technology them, or appraisal guidance 313 •the person has had a TNF alpha inhibitor before. Treatment with ustekinumab should be stopped after 24 weeks if it is not 1 working well enough. 01/06/2015 TA341 - Apixaban for the treatment and secondary prevention Apixaban (Eliquis) is recommended as an option for treating and preventing of deep vein thrombosis X 30/08/2015 01/06/2015 0 recurrent deep vein thrombosis or pulmonary embolism. and/or pulmonary embolism- technology appraisal guidance 1 01/06/2015 Vedolizumab (Entyvio) is recommended as a possible treatment for adults with moderate to severe ulcerative colitis. People should be able to have the treatment until it stops working or surgery is TA342 - Vedolizumab needed. Their condition should be assessed 12 months after they started for treating moderately taking vedolizumab. If they still have symptoms but it is clear that the treatment to severely active is helping, they can continue to have it. If they no longer have symptoms, X 30/08/2015 19/10/2015 140 ulcerative colitis- treatment could be stopped, and later restarted if symptoms return. technology appraisal guidance People who continue to take vedolizumab should be assessed at least every 12 months to see whether the treatment is working well enough for them to carry on taking it. 1 01/06/2015 Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic TA343 - Obinutuzumab lymphocytic leukaemia only if: in combination with chlorambucil for •they have other conditions that make full-dose fludarabine unsuitable for them X 30/08/2015 17/07/2015 46 untreated chronic and lymphocytic leukaemia •bendamustine is not suitable for them. – guidance What does this mean for me? 1 01/06/2015 Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended TA344 - Ofatumumab in as a possible treatment for people with untreated chronic lymphocytic combination with leukaemia if treatments containing fludarabine or bendamustine are not chlorambucil or suitable. X 30/08/2015 15/09/2015 106 bendamustine for untreated chronic Ofatumumab (with chlorambucil) should be available on the NHS within 3 lymphocytic leukaemia 1 months of the guidance being issued. 01/07/2015 Naloxegol (Moventig) is recommended as a possible treatment for people with TA345 - Naloxegol for opioid induced constipation that has had an inadequate response to laxatives. treating opioid‑induced X 29/09/2015 19/10/2015 110 constipation 1 01/07/2015 Aflibercept (Eylea) injections are recommended as a possible treatment for TA346 - Aflibercept for some people with sight problems caused by diabetic macular oedema, as treating diabetic explained below. X 29/09/2015 24/08/2015 54 macular oedema 1 TA347 - Nintedanib for 01/07/2015 Nintedanib (Vargatef), given with a drug called docetaxel, is recommended. It previously treated is a possible treatment for people with a certain type (adenocarcinoma) of locally advanced, locally advanced, metastatic or locally recurrent non-small-cell lung cancer metastatic, or locally that has got worse after previous chemotherapy. X 29/09/2015 24/08/2015 54 recurrent non‑small‑cell lung cancer 1 TA348 - Everolimus for 01/07/2015 Everolimus (Certican) is not recommended for preventing organ rejection in preventing organ people having a liver transplant. rejection in liver X 29/09/2015 24/08/2015 54 transplantation 1 01/07/2015 Dexamethasone intravitreal implant (Ozurdex) is recommended as a possible TA349 - treatment for people with sight problems caused by diabetic macular oedema Dexamethasone if: intravitreal implant for X 29/09/2015 24/08/2015 54 treating diabetic •there is an artificial lens in the eye to be treated, and macular oedema •their diabetic macular oedema has not improved with non‑corticosteroid treatment, or such treatment is not suitable for them. 1 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 01/07/2015 Secukinumab (Cosentyx) is recommended as a possible treatment for people with plaque psoriasis if: •standard assessments show that their psoriasis is severe and is affecting their quality of life, and TA350 - Secukinumab •their psoriasis has not improved with other treatments including ciclosporin, for treating moderate to methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they X 29/09/2015 18/05/2015 -44 severe plaque psoriasis have had side effects with these treatments in the past or there is a reason why they cannot have them. Treatment with secukinumab should be stopped after 12 weeks if the psoriasis does not improve enough according to standard measures. 1 01/07/2015 NICE is unable to make a recommendation about the use in the NHS of TA351 - Cangrelor for cangrelor for reducing atherothrombotic events in people undergoing reducing percutaneous coronary intervention or awaiting surgery requiring interruption atherothrombotic of anti-platelet therapy because no evidence submission was received from events in people The Medicines Company undergoing percutaneous coronary X 29/09/2015 21/09/2015 82 intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) 1 01/08/2015 TA352 Vedolizumab for Vedolizumab (Entyvio) is recommended. It is a possible option for adults with treating moderately to moderate to severe Crohn’s disease if a type of treatment called a tumour severely active Crohn's X 30/10/2015 19/10/2015 79 necrosis factor (TNF) alpha inhibitor isn’t suitable or hasn’t worked well disease after prior enough. therapy 1 TA353 Bevacizumab 01/08/2015 NICE is unable to make a recommendation about the use in the NHS of for treating relapsed, bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, platinum resistant fallopian tube or primary peritoneal cancer because no evidence submission epithelial ovarian, was received from Roche Products for the technology. X 30/10/2015 21/09/2015 51 fallopian tube or primary peritoneal cancer (terminated 1 appraisal) 01/08/2015 Edoxaban (Lixiana) is recommended as an option for treating and TA354 Edoxaban for treating and for preventing recurrent deep vein thrombosis or pulmonary embolism. preventing deep vein X 30/10/2015 14/12/2015 135 thrombosis and pulmonary embolism 1 01/10/2015 Pembrolizumab for treating advanced melanoma after disease TA357 progression with ipilimumab Pembrolizumab for treating advanced X 30/12/2015 26/10/2015 25 melanoma after disease progression with ipilimumab 1 TA355 Edoxaban for 01/09/2015 Edoxaban for preventing stroke and systemic embolism in people with preventing stroke and non‑valvular atrial fibrillation systemic embolism in X 30/11/2015 14/12/2015 104 people with non‑valvular atrial 1 fibrillation 01/09/2015 Ruxolitinib for treating polycythaemia vera (terminated appraisal) TA356 Ruxolitinib for treating X 30/11/2015 26/10/2015 55 polycythaemia vera (terminated appraisal) 1 TA358 Tolvaptan for 01-Oct-15 Tolvaptan (Jinarc) is recommended as a possible treatment for people treating autosomal with autosomal dominant polycystic kidney disease if: dominant polycystic kidney disease • they have chronic kidney disease stage 2 or 3 at the start of X 31/12/2015 18/01/2016 109 . treatment and • there is evidence of rapidly progressing disease. 1 TA359